Qingfei Xiaoyan Wan Alleviates Asthma Through Multi-target Network Regulation

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2013 Aug 8

PMID 23919426

Citations 6

Authors

Zhenying Zhao

Yingbo Miao

Pengwei Pan

Binfeng Cheng

Gang Bai

Hong Wu

Affiliations

Soon will be listed here.

Abstract

Background: Qingfei Xiaoyan Wan (QFXY), a traditional Chinese formula, is widely used for relieving cough, asthma, upper respiratory tract infection, bronchitis, pneumonia, and etc. in clinic. Comparing with other anti-asthma drugs, it is characterised with moderate and persistent efficacy as well as few side effects, however, the underlying action mechanism still remains elusive. This study aimed to identify QFXY multi-target network regulation as an asthma controller.

Methods: This study established asthma model induced by histamine phosphate and acetylcholine chloride (His&Ach) in guinea pigs, which then were administered orally with QFXY. Hematoxylin-Eosin staining sections were applied for evaluating QFXY effect. In both Model and QFXY groups, customized microarrays and 2D electrophoresis were adopted to detect differentially expressed genes (diff genes) and proteins (diff proteins) respectively, and some diff proteins were identified with MALDI-TOF/MS. The checked diff genes and proteins underwent Cluster, GO and KEGG analysis. Based on GAD and HPRD databases, QFXY-asthma target regulation network was constructed.

Results: His&Ach-induced asthma model of guinea pigs was established. HE sections presented anti-inflammation and anti-remodelling effects of QFXY. Comparing with the Model group, 55 diff genes and 6 diff proteins were identified in QFXY group. Validation by qPCR and Western blot showed the microarray and 2D data reliable. Furthermore, QFXY-asthma target regulation network was achieved.

Conclusions: A primarily combined genomic and proteomic screening of QFXY targets displayed a series of candidate genes and proteins, which indicated that the effect of QFXY relied on the combined mechanism, anti-inflammation and anti-remodelling, as well as influencing signal transduction in vivo.

Citing Articles

Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses.

Hou J, Wu J, Chen Y, Xu D, Liu S, Shang D Pharm Biol. 2022; 60(1):743-754.

PMID: 35357989 PMC: 8979529. DOI: 10.1080/13880209.2022.2055090.

Traditional Chinese Medicine is an Alternative Therapeutic Option for Treatment of Infections.

Pang Z, Zhu Q Front Pharmacol. 2021; 12:737252.

PMID: 34512364 PMC: 8429605. DOI: 10.3389/fphar.2021.737252.

Immune Homeostasis: Effects of Chinese Herbal Formulae and Herb-Derived Compounds on Allergic Asthma in Different Experimental Models.

Liu L, Wang L, He S, Ma Y Chin J Integr Med. 2018; 24(5):390-398.

PMID: 29752613 DOI: 10.1007/s11655-018-2836-2.

DNA Microarray-Based Screening and Characterization of Traditional Chinese Medicine.

Kiyama R Microarrays (Basel). 2017; 6(1).

PMID: 28146102 PMC: 5374364. DOI: 10.3390/microarrays6010004.

Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa-induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways.

Hou Y, Nie Y, Cheng B, Tao J, Ma X, Jiang M Acta Pharm Sin B. 2016; 6(3):212-21.

PMID: 27175332 PMC: 4856955. DOI: 10.1016/j.apsb.2016.03.002.

References

Boulet L, Turcotte H, Laviolette M, Naud F, Bernier M, Martel S . Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1308-13. DOI: 10.1164/ajrccm.162.4.9910051. View

Shigetomi H, Onogi A, Kajiwara H, Yoshida S, Furukawa N, Haruta S . Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain. Inflamm Res. 2010; 59(9):679-87. DOI: 10.1007/s00011-010-0205-5. View

Bateman E, Hurd S, Barnes P, Bousquet J, Drazen J, Fitzgerald J . Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1):143-78. DOI: 10.1183/09031936.00138707. View

Szelenyi I . Animal models of bronchial asthma. Inflamm Res. 2001; 49(12):639-54. DOI: 10.1007/s000110050642. View

Mutter G, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker H . Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004; 5:88. PMC: 534099. DOI: 10.1186/1471-2164-5-88. View

Perkins N . Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 2006; 25(51):6717-30. DOI: 10.1038/sj.onc.1209937. View

Zhang B, Hu Y, Ma J . Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. Invest Ophthalmol Vis Sci. 2009; 50(8):3943-52. DOI: 10.1167/iovs.08-2954. View

Canning B . Modeling asthma and COPD in animals: a pointless exercise?. Curr Opin Pharmacol. 2003; 3(3):244-50. DOI: 10.1016/s1471-4892(03)00045-6. View

Bostrom K, Zebboudj A, Yao Y, Lin T, Torres A . Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem. 2004; 279(51):52904-13. DOI: 10.1074/jbc.M406868200. View

10.

Sato S, Fujita N, Tsuruo T . Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A. 2000; 97(20):10832-7. PMC: 27109. DOI: 10.1073/pnas.170276797. View

11.

Pedotti P, t Hoen P, Vreugdenhil E, Schenk G, Vossen R, Ariyurek Y . Can subtle changes in gene expression be consistently detected with different microarray platforms?. BMC Genomics. 2008; 9:124. PMC: 2335120. DOI: 10.1186/1471-2164-9-124. View

12.

Claudio L, Tulton L, Doucette J, Landrigan P . Socioeconomic factors and asthma hospitalization rates in New York City. J Asthma. 1999; 36(4):343-50. DOI: 10.3109/02770909909068227. View

13.

Cheng B, Hou Y, Wang L, Dong L, Peng J, Bai G . Dual-bioactivity-based liquid chromatography-coupled quadrupole time-of-flight mass spectrometry for NF-κB inhibitors and β2AR agonists identification in Chinese Medicinal Preparation Qingfei Xiaoyan Wan. Anal Bioanal Chem. 2012; 404(8):2445-52. DOI: 10.1007/s00216-012-6332-9. View

14.

Wechsler M, Pauwels R, Drazen J . Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?. Drug Saf. 1999; 21(4):241-51. DOI: 10.2165/00002018-199921040-00001. View

15.

Kitanaka J, Kitanaka N, Takemura M, Wang X, Hembree C, Goodman N . Isolation and sequencing of a putative promoter region of the murine G protein beta 1 subunit (GNB1) gene. DNA Seq. 2002; 13(1):39-45. DOI: 10.1080/10425170290019883. View

16.

Fan X, Shi M, Wang Y, Liang Q, Luo G . Transcriptional profiling analysis of HMP-treated rats with experimentally induced myocardial infarction. J Ethnopharmacol. 2011; 137(1):199-204. DOI: 10.1016/j.jep.2011.05.010. View

17.

Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161(5):1720-45. DOI: 10.1164/ajrccm.161.5.9903102. View

18.

Budd D, Holmes A . Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012; 135(3):279-91. DOI: 10.1016/j.pharmthera.2012.06.001. View

19.

Holgate S, Davies D . Rethinking the pathogenesis of asthma. Immunity. 2009; 31(3):362-7. DOI: 10.1016/j.immuni.2009.08.013. View

20.

Vignola A, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V . Airway remodeling in asthma. Chest. 2003; 123(3 Suppl):417S-22S. DOI: 10.1378/chest.123.3_suppl.417s. View